High magnetic field thermal-expansion and elastic properties of CeRhIn5_5

We report high magnetic field thermal-expansion and magnetostriction results on CeRhIn$_5$ single crystals. Several transitions, both first and second order, are observed when the field is applied perpendicular to the crystallographic c-axis. The magnetic field dependence of the thermal-expansion coefficient above 15 K, where the magnetic correlations are negligible, can be explained supposing an almost pure $| \pm 5/2>$ ground state doublet, in apparent contradiction with neutron scattering experiments. Although the spin-lattice interaction is relevant in this compound, the effect of the magnetic correlations on the elastic properties is relatively weak, as revealed by resonant ultrasound spectroscopy experiments.Comment: 5 pages, 6 figure

Elastic and thermodynamic properties of the shape-memory alloy AuZn

The current work reports on the elastic shear moduli, internal friction, and the specific heat of the B2 cubic ordered alloy AuZn as a function of temperature. Measurements were made on single-crystal and polycrystalline samples using Resonant Ultrasound Spectroscopy (RUS), semi-adiabatic calorimetry and stress-strain measurements. Our results confirm that this alloy exhibits the shape-memory effect and a phase transition at 64.75 K that appears to be continuous (second-order) from the specific heat data. It is argued that the combination of equiatomic composition and a low transformation temperature constrain the chemical potential and its derivatives to exhibit behavior that lies at the borderline between that of a first-order (discontinuous) and a continuous phase transition. The acoustic dissipation does not peak at the transtion temperature as expected, but shows a maximum well into the low-temperature phase. The Debye temeprature value of 219 K, obtained from the low-temperature specific heat data is in favorable agreement with that determined from the acoustic data (207 K) above the transition.Comment: 25 pages, 6 figures, submitted to Phys. Rev.

Improving tuberculosis surveillance in Europe is key to controlling the disease.

As underlined by the joint ECDC and World Health Organization Regional Office for Europe TB report, launched on 18 March the importance of good surveillance to stem this trend cannot be underestimated. Where do we go with surveillance in Europe? Can we do more? How many MDR and XDR TB cases occur because of sub-optimal patient management? This issue of Eurosurveillance casts light on these important questions with four interesting articles. The results of the studies reported in this issue of Eurosurveillance allow us to point out some key topics: \u2022The completeness of reporting information (including treatment outcomes), the proportion of culture-confirmed TB cases reported as well as the proportion of strains on which DST for both first- and second-line drugs is performed and reported are still sub-optimal overall in Europe. The relevance of these pitfalls goes beyond the \u201csimple\u201d surveillance limitation, having the potential to affect other important TB control pillars, e.g. infection control and case-management. \u2022MDR and XDR TB still persist in Europe. The high proportion of MDR TB identified among new TB cases reported by certain countries indicates that sub-optimal infection control practices are likely to occur, while the high percentage of MDR TB notified among retreatment cases is probably the result of sub-optimal case management in the past decade

Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India.

Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is little prospective data on AE in MDR- or XDR-TB/HIV co-infected patients on antituberculosis and antiretroviral therapy (ART) in programmatic settings

An innovative approach for DEMO core fuelling by inboard injection of high-speed pellets

Core fuelling of DEMO tokamak fusion reactor is under investigation within the EUROfusion Work Package “Tritium, Fuelling and Vacuum”. An extensive analysis of fuelling requirements and technologies, suggests that pellet injection still represents, to date, the most realistic option. Modelling of both pellet penetration and fuel deposition profiles for different injection locations, assuming a specific plasma reference scenario and the ITER reference pellet mass (6 × 1021 atoms), indicates that: 1) Low Field Side (LFS) injection is inadequate; 2) Vertical injection may be effective only provided that pellets are injected at ∼ 10 km/s from a radial position ≤∼8 m; 3) effective core fuelling can be achieved launching pellets from the High Field Side (HFS) at ∼1 km/s. HFS injection was therefore selected as the reference scheme, though scenarios featuring less steep density and temperature gradients at the plasma edge could induce to reconsider vertical injection at speeds in the range of 4–5 km/s. To deliver intact pellets at 1 km/s from the HFS, the use of guide tubes with a bend radius ≥6 m is envisaged. The results of above simulations rely on the hypothesis that pellets are delivered at the plasma edge with the desired mass and speed. However, mass erosion and fracturing of pellets inside the guide tube (severely limiting the transfer speed), as well as pressure build up and speed losses at relevant injection rates, might hamper the use of curved guide tubes. An additional innovative approach, aimed at identifying inboard straight “free flight” injection paths, to inject pellets from the HFS at significantly higher speeds, is proposed and discussed as a backup solution. Outboard high-speed injection is still being considered, instead, for JT-60SA

Multiresistentse tuberkuloosi ravi kulutulusus ja ravitulemused erinevate ravistrateegiate rakendamisel

Järjest laialdasemalt rakendatakse multiresistentse tuberkuloosi haigete raviks DOTS-Plus strateegiat, kasutades teise rea ravimeid, kuid teadmised nende efektiivsuse ja kulutulususe kohta on vähesed. Uuringus hinnati alates 2001. a augustist Eestis rakendatud DOTS-Plus strateegia tõhusust, maksumust ja kulutulusust võrreldes 3 alternatiivset ravi strateegiat: DOTS-Plus strateegia, pre-DOTS-plus strateegia ja DOTS-strateegia. Kulud arvutati 2002. a kehtinud hindades, tõhususe näitajateks olid tuberkuloosist põhjustatud surmade arv, kaotatud haiguskoormus ja kulutulususe näitajaks säästetud haiguskoormuse maksumus. Saadud andmete alusel võib väita, et kasutades DOTS-Plus strateegiat, on võimalik oluliselt paran dada multiresistentse tuberkuloosi haigete ravitulemusi ning võrreldes teiste võimalustega on see kulutulusaim. Eesti Arst 2006; 85 (3): 148–15